Carlo Tondini
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown L, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller-Hübenthal B, Jochum W, Bonnefoi H, Martino S, Davidson N, Geyer C, Chia S, Ingle J, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming G, Francis P, Speed T, Regan M, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023; 34:397-409.
25.01.2023Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
25.01.2023Ann Oncol 2023; 34:397-409
Luen Stephen J, Viale Giuseppe, Nik-Zainal S, Savas Peter, Kammler Roswitha, Dell'Orto Patrizia, Biasi Olivia Maria, Degasperi A, Brown Louise C, Láng István, MacGrogan Gaëtan, Tondini Carlo, Bellet Meritxell, Villa F, Bernardo A, Ciruelos Eva, Karlsson Per, Neven Patrick, Climent Miguel A, Müller-Hübenthal Boris, Jochum Wolfram, Bonnefoi Hervé R, Martino Silvana, Davidson Nancy E, Geyer Charles E, Chia S K, Ingle James N, Coleman Robert E, Solbach Christine, Thürlimann Beat, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Fleming Gini F, Francis Prudence A, Speed T P, Regan Meredith M, Loi Sherene
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol 2018:JCO1800440.
26.11.2018Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
26.11.2018J Clin Oncol 2018:JCO1800440
Ruhstaller Thomas, Simoncini Edda, Gianni Lorenzo, Rochlitz Christoph, Kralidis Elena, Zaman Khalil, Jassem Jacek, Piccart-Gebhart Martine, Di Leo Angelo, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Thürlimann Beat, Regan Meredith M, Veyret Corinne, Del Mastro Lucia, Giobbie-Hurder Anita, Colleoni Marco, Jensen Maj-Britt, Ejlertsen Bent, de Azambuja Evandro, Neven Patrick, Láng István, Jakobsen Erik Hugger, Gladieff Laurence, Bonnefoi Hervé, Harvey Vernon J, Spazzapan Simon, Tondini Carlo, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Galimberti V, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan M, Coates A, Gelber R, Goldhirsch A, Littlejohn D, Taffurelli M, Cole B, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018
05.09.2018Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
05.09.2018Lancet Oncol 2018
Galimberti Viviana, Knauer Michael, Tondini Carlo, Di Leo Angelo, Colleoni Marco, Regan Meredith M, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Littlejohn David, Taffurelli Mario, Cole Bernard F, Viale Giuseppe, Veronesi Paolo, Vicini Elisa, Intra Mattia, Mazzarol Giovanni, Massarut Samuele, Zgajnar Janez, International Breast Cancer Study Group Trial 23-01
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis P, Pavesi L, Ruhstaller T, Davidson N, Coleman R, Debled M, Buchholz S, Ingle J, Winer E, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates A, Gelber R, Goldhirsch A, Regan M, Climent M, Spazzapan S, Puglisi F, Pagani O, Fleming G, Walley B, Colleoni M, Láng I, Gomez H, Tondini C, Ciruelos E, Burstein H, Bonnefoi H, Bellet M, Martino S, Geyer C, Goetz M, Stearns V, Pinotti G, SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018; 379:122-137.
04.06.2018Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
04.06.2018N Engl J Med 2018; 379:122-137
Francis Prudence A, Pavesi Lorenzo, Ruhstaller Thomas, Davidson Nancy E, Coleman Robert, Debled Marc, Buchholz Stefan, Ingle James N, Winer Eric P, Maibach Rudolf, Rabaglio-Poretti Manuela, Ruepp Barbara, Di Leo Angelo, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Regan Meredith M, Climent Miguel A, Spazzapan Simon, Puglisi Fabio, Pagani Olivia, Fleming Gini F, Walley Barbara A, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Ciruelos Eva, Burstein Harold J, Bonnefoi Hervé R, Bellet Meritxell, Martino Silvana, Geyer Charles E, Goetz Matthew P, Stearns Vered, Pinotti Graziella, SOFT and TEXT Investigators and the International Breast Cancer Study Group
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016
20.06.2016Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
20.06.2016J Clin Oncol 2016
Colleoni Marco, Eniu Alexandru, Cagossi Katia, Rauch Daniel, Chirgwin Jacquie, Gelber Richard D, Regan Meredith M, Coates Alan S, Price Karen N, Viale Giuseppe, Kralidis Elena, Tondini Carlo, Gray Kathryn P, Gelber Shari, Láng István, Thürlimann Beat, Gianni Lorenzo, Abdi Ehtesham A, Gomez Henry L, Linderholm Barbro K, Puglisi Fabio, Goldhirsch Aron
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 2016; 34:1601-10.
28.03.2016Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
28.03.2016J Clin Oncol 2016; 34:1601-10
Ribi Karin, Torres Roberto, Lombardi Davide, Puglisi Fabio, Karlsson Per, Ruhstaller Thomas, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Price Karen N, Gelber Richard D, Regan Meredith M, Neven Patrick, Perelló Antonia, Kerbrat Pierre, Luo Weixiu, Bernhard Jürg, Francis Prudence A, Burstein Harold J, Ciruelos Eva, Bellet Meritxell, Pavesi Lorenzo, Lluch Ana, Visini Marilena, Parmar Vani, Tondini Carlo, Fleming Gini F
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848-58.
16.06.2015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
16.06.2015Lancet Oncol 2015; 16:848-58
Bernhard Jürg, Regan Meredith M, Pagani Olivia, Fleming Gini F, Francis Prudence A, Price Karen N, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Parmar Vani, Pavesi Lorenzo, Puglisi Fabio, Luo Weixiu, Ribi Karin, Colleoni Marco, Burstein Harold J, Tondini Carlo, Pinotti Graziella, Spazzapan Simon, Ruhstaller Thomas, Walley Barbara A
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
01.06.2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
01.06.2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.
01.02.2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
01.02.2014Breast Cancer Res Treat 2014; 144:321-9
Decensi Andrea, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Price Karen N, Johansson Harriet, Zaman Khalil, Schönenberger Astrid, Debled Marc, Campone Mario, Monnier Alain, Tondini Carlo, McIntosh Christina, Thürlimann Beat, Guerrieri-Gonzaga Aliana, Sun Zhuoxin, Aebi Stefan